Kadmon (NYSE:KDMN) Downgraded to Sell at ValuEngine
KDMN has been the topic of several other reports. Cantor Fitzgerald upped their price target on Kadmon from $8.00 to $10.00 and gave the stock an overweight rating in a research note on Tuesday. Zacks Investment Research cut Kadmon from a buy rating to a hold rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $9.35.
Shares of Kadmon stock traded up $0.36 during midday trading on Wednesday, reaching $3.92. 12,099,500 shares of the company’s stock traded hands, compared to its average volume of 930,109. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.29 and a current ratio of 2.29. The company has a market cap of $461.70 million, a PE ratio of -3.81 and a beta of 2.22. The stock has a 50 day moving average of $2.85 and a 200-day moving average of $2.43. Kadmon has a 12 month low of $1.63 and a 12 month high of $4.35.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Featured Article: What are the benefits of momentum investing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.